Carriage of Clostridium difficile in outpatients with irritable bowel syndrome
|
|
- Scot Lane
- 5 years ago
- Views:
Transcription
1 Journal of Medical Microbiology (2012), 61, DOI /jmm Carriage of Clostridium difficile in outpatients with irritable bowel syndrome Evelyn M. Clayton, 1,2 Mary C. Rea, 1,2 Fergus Shanahan, 2,3 Eamonn M. M. Quigley, 2,3 Barry Kiely, 4 R. Paul Ross 1,2 and Colin Hill 2,5 Correspondence R. P. Ross paul.ross@teagasc.ie 1 Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland 2 Alimentary Pharmabiotic Centre, University College, Cork, Ireland 3 Department of Medicine, University College, Cork, Ireland 4 Alimentary Health, Cork Airport Business Park, Cork, Ireland 5 Department of Microbiology, University College, Cork, Ireland Received 10 November 2011 Accepted 7 May 2012 Irritable bowel syndrome (IBS) is a common, typically chronic and sometimes disabling gastrointestinal condition of uncertain aetiology. Recently, a variety of links to gastrointestinal infections have been described including the onset of IBS following exposure to enteric pathogens and an apparent predisposition to gastrointestinal infection. The prevalence of Clostridium difficile in a population of IBS outpatients (n587) in the absence of established risk factors for the acquisition of C. difficile infection was examined. Overall, 5.7 % of patients (n55) carried culturable C. difficile and 4.6 % (n54) of isolates were toxigenic, belonging to toxinotype group 0, compared with 1.1 % (n51) for the healthy control group (n588). These isolates were members of toxigenic PCR ribotype groups 005 and 050 (IBS group) and 062 (control group) and were identified further as three individual strains by PFGE. Although no significant difference was observed between IBS patients and healthy volunteers, these findings support the concept that a subpopulation of IBS patients may be susceptible to gastrointestinal infection. INTRODUCTION Irritable bowel syndrome (IBS) is a common disorder that manifests as abdominal discomfort associated with a variety of disturbances of bowel function (Drossman et al., 2002; Quigley, 2006). Alterations in the intestinal microbiota and the mucosal immune response have been described in IBS and have led to the speculation that this disorder may result from a fundamental abnormality in the interaction between the luminal flora and the host and could be traced to a previous episode of bacterial gastroenteritis (Parkes et al., 2008; Quigley, 2007; Spiller, 2007). Whilst persistent inflammatory IBS may represent a minority of IBS subjects, research on this particular population has shown how, in a susceptible subject, an enteric pathogen that in other circumstances would lead to a selflimited gastroenteritis can result in a persistent inflammatory response and chronic symptoms (Spiller, 2003). Based initially on the assumption that some IBS subjects may harbour small-intestinal bacterial overgrowth, antibiotic usage has been studied in IBS and has demonstrated some benefits in terms of symptom relief (Mättö et al., Abbreviations: APC, Alimentary Pharmabiotic Centre; CDT, C. difficile transferase toxin; IBS, irritable bowel syndrome; PaLoc, pathogenicity locus; VPI, Virginia Polytechnic Institute. 2005; Pimentel et al., 2000, 2006; Sharara et al., 2006). These observations raise an important question: is a subgroup of the IBS population susceptible to enteric infection and, specifically, given the current enthusiasm for treating these patients with antibiotics, could some IBS subjects harbour one of the most important opportunistic pathogenic species such as antibiotic-resistant toxigenic Clostridium difficile? This pathogen can induce diarrhoeal symptoms similar to those experienced by some in an exacerbation of IBS (Borody et al., 1989). For these reasons, we investigated the carriage of C. difficile in IBS patients in the absence of known risk factors to C. difficile infection to ascertain whether a predisposition to infection exists. METHODS Study populations. IBS patients (n587, all female) were recruited from gastroenterology clinics at Cork University Hospital, Ireland, and by direct advertisement on the university campus and in the local newspaper. Individuals aged between 19 and 71 years who satisfied the Rome II criteria for the diagnosis of IBS, but for whom organic gastrointestinal diseases such as inflammatory bowel disease were ruled out, were included in the study group. Pregnant individuals, those with known lactose intolerance or immunodeficiency and those who had undergone prior gastrointestinal surgery, with the exception of inguinal hernia repair and appendectomy, were excluded. The G 2012 SGM Printed in Great Britain
2 Clostridium difficile carriage in IBS patients control group comprised 88 healthy female volunteers who were free of gastrointestinal symptoms, with ages ranging from 18 to 65 years. Isolation and identification of C. difficile strains. Faecal samples were collected within 48 h and immediately frozen at 280 uc until required for analysis. C. difficile was isolated from ethanol-treated stool samples and selected on cycloserine-cefoxitin egg yolk agar (Lab M). Non-haemolytic and lecithinase-negative colonies of typical morphology were subsequently subcultured onto reinforced clostridial agar (Merck) and assessed for fluorescence under UV light. Isolates were examined by Gram staining and for L-proline aminopeptidase activity (PRO kit; Remel). C. difficile was routinely cultured on fastidious anaerobe agar (Lab M). A single colony was inoculated into 10 ml pre-reduced brain heart infusion broth (Merck) and grown anaerobically for 18 h at 37 uc. Genomic DNA was extracted as described previously (Cartwright et al., 1995). Presumptive C. difficile was identified by 16S rrna gene sequencing using primer pairs and PCR cycling conditions described previously (Simpson et al., 2003). Amplified fragments of 1.5 kb were purified (QIAquick PCR Purification kit; Qiagen) and sequenced by Lark Technologies. Overlapping contiguous sequences and a consensus sequence were determined using the Seqmanager program (Lasergene 6; DNASTAR). Sequences homologous to C. difficile were identified using BLAST by scanning with all available nucleotide databases for high-scoring sequence pairs. Toxin production. In vitro production of the C. difficile TcdA and TcdB toxins was assessed from culture supernatants using enzyme immunoassays. Production of TcdA was demonstrated by a Toxin A assay (Remel), and the Toxin A/B assay (Remel) was used to identify toxin variant isolates (TcdA 2, TcdB + ). The following C. difficile strains were included for control purposes: ATCC (TcdA +, TcdB + ), ATCC (TcdA 2, TcdB 2 ) and CCUG (TcdA 2, TcdB + ). Antimicrobial susceptibility testing. An Etest system (AB Biodisk) was used to screen isolates for antibiotic resistance to vancomycin, metronidazole, ampicillin and clindamycin. The Etest was performed on test cultures inoculated onto fastidious anaerobe agar (Lab M) containing 6 % lysed horse blood and interpreted following the manufacturer s instructions. Bacteriodes fragilis (ATCC 25285) was included as an internal control for the system. Individual MICs were recorded, and MIC 90 was defined as the MIC observed to impede the growth of 90 % of the isolates tested (Jamal et al., 2002). Strains were deemed susceptible or resistant to the test antibiotic according to documented pharmacological breakpoint values. Toxinotyping. Toxinotyping is based on a PCR RFLP analysis of variable regions of the tcda and tcdb genes, encoding the major C. difficile toxins TcdA and TcdB. Strains were screened for variation in the first 3.1 kb of tcdb (B1 fragment) and a 3.1 kb fragment spanning the repetitive region of tcda (A3 fragment) using primer pairs and methodology described previously (Rupnik et al., 1998). The B1 and A3 fragments of the tcdb and tcda genes were amplified using the BIOTAQ DNA polymerase system (Bioline) and gel purified (QIAquick PCR Purification kit). Fragments were then digested with AccI and HincII (B1) or EcoRI (A3) (New England Biolabs) and checked for length polymorphisms. Profiles were compared with the reference strains VPI (toxinotype 0), VIII and VI (reference DNA kindly supplied by Professor M. Rupnik, University of Maribor, Slovenia). The accessory genes tcdd, tcde and tcdc and genes flanking the pathogenicity locus (PaLoc) integration sites cdu-2 and cdd-3 were amplified using BIOTAQ DNA polymerase using primer pairs and a methodology as described previously (Braun et al., 1996). The tcdc gene was amplified as a 718 bp fragment using primer pairs described previously using the KOD Hot Start Polymerase system (Novagen) and sequenced (Spigaglia & Mastrantonio, 2002). Amino acid sequences were compared with the published tcdc sequence for VPI (kindly supplied by Dr Scott Curry; Curry et al., 2007), by pairwise and multiple sequence alignments using CLUSTAL W in the MEGALIGN program of Lasergene 6. Finally, internal regions of the two-component binary toxin (actin-specific ADP-ribosyltransferase) gene (cdt) were amplified again with KOD polymerase as described previously (Stubbs et al., 2000): primers cdtapos and cdtarev amplified a 510 bp fragment of the enzymic component (cdta), and cdtbpos and cdtbrev amplified a 375 bp fragment of the binding component (cdtb). Primers amplifying sequences encompassing the entire gene were used to confirm the absence of binary toxin genes in all cases (Spigaglia & Mastrantonio, 2002): primers BIN5 and BIN6 amplified a 1158 bp product encompassing the cdta gene, and BIN7 and BIN8 amplified a 2751 bp product encompassing cdtb. Controls representing C. difficile CCUG and PCR ribotype 001 were used as positive and negative controls for the binary toxin. PCR ribotyping. PCR ribotyping analysis is based on a comparison of patterns of PCR products generated from the 16 23S rrna gene intergenic region. Primers complementary to the 39 end of the 16S rrna gene and the 59 end of the 23S rrna gene were used to amplify the variable length 16 23S intergenic spacer region, as described previously (Stubbs et al., 1999). Ribotype banding patterns were analysed by gel electrophoresis in 3 % Metaphor agarose (FMC Bioproducts) for 3.5 h at 65 ma and visualized under UV light. Profiles were compared with clinically significant strains common to Ireland and the UK, including the epidemic strain described as North American pulsed-field type 1, PCR ribotype 027 (NAP1/027) and PCR ribotypes 001 and 106. Banding patterns were photographed using a Gel-Doc 2000 System (Bio-Rad) and patterns were subsequently identified by the Anaerobe Reference Laboratory (Cardiff, UK) by comparison with a library of known PCR ribotypes. PFGE analysis. PFGE was performed as described previously (Clayton et al., 2009). Genomic DNA was prepared in agarose plugs, lysed and digested with SmaI (New England Biolabs). Electrophoresis was performed using the CHEF-DR II system (Bio-Rad) and DNA macrorestriction patterns were stored as TIFF files and imported into BioNumerics software (version 3; Applied Maths) for dendrographic analysis. Gels were normalized using standard PFGE molecular mass markers (New England Biolabs) ranging from 48.5 to kb (l ladder) and 2.03 to kb (low-range marker). The Dice coefficient of similarity was calculated and UPGMA was used for cluster analysis with optimization set at 1.3 % and position tolerance set at 0.9 %. The genetic relatedness to NAP1/027 and PCR ribotypes 001 and 106 was also assessed. Data analysis and statistics. The proportion of patients testing positively for faecal C. difficile in IBS patients compared with the proportion in healthy controls was assessed by Fisher s exact test and values of P,0.05 were considered statistically significant. RESULTS Carriage of C. difficile in IBS outpatients In this study, 87 female IBS patients whose diagnosis satisfied the Rome II criteria were screened for the presence of C. difficile. In terms of IBS subtype, 17 (19.5 %) were diarrhoea predominant, 22 (25.3 %) were constipation predominant and 48 (55.2 %) reported an alternating bowel habit. Table 1 summarizes the frequency of C. difficile carriage and the IBS status of individual carriers. Overall, 5.7 % (n55) of patients carried culturable C. difficile compared with 1.1 % (n51) for
3 E. M. Clayton and others Table 1. Details of the five C. difficile-positive isolates from IBS outpatients Of the five C. difficile-positive isolates from IBS outpatients (5.7 %), four (4.6 %) were toxigenic. One subject from the control group (n588) also carried a toxigenic isolate (APC14). APC, Alimentary Pharmabiotic Centre. Patient isolate ID Patient age (years) Duration of IBS/type APC years/ibs-a APC years/ibs-d APC years/ibs-c APC years/ibs-a APC years/ibs-a the control group. It is noteworthy that only one of the C. difficile-positive patients had diarrhoea-predominant IBS. All isolates were susceptible to metronidazole and vancomycin (MIC 90 of 1.5 and 0.75 mg ml 21, respectively) and ampicillin (MIC 90 of 1.0 mg ml 21 ); however, an MIC 90 of 4.0 mg ml 21 was found for clindamycin, indicating resistance. Five isolates (four from the IBS group and one from the control group) were toxigenic, as shown by enzyme immunoassays. In this respect, production of the primary toxins TcdA and TcdB was demonstrated using a toxin A/B assay. The toxin A assay indicated that variant strains that produced TcdB alone (TcdA 2, TcdB + ) were not isolated. The carriage rate among IBS patients was not significantly increased (P50.21, Fisher s exact test) when compared with the control group, where 1.1 % (1/88) of the population harboured toxigenic C. difficile. Toxinotyping and tcdc analysis TcdA and TcdB are encoded by the tcda and tcdb genes and, together with the three accessory genes tcdr, tcde and tcdc, form part of a 19.6 kb chromosomal unit (PaLoc; Fig. 1) (Braun et al., 1996; Lyerly et al., 1985). Some strains also produce a binary toxin an actin-specific ADP-ribosyltransferase referred to as the C. difficile transferase (CDT) toxin (Popoff et al., 1988). CDT is a two-component toxin encoded by the cdta and cdtb genes, which are located on a specific region of the chromosome outside the PaLoc, termed the C. difficile transferase locus (CdtLoc; Fig. 1) (Carter et al., 2007). The expected PCR fragments for the tcda and tcdb genes and the accessory genes tcdd (300 bp), tcde (262 bp) and tcdc (345 bp) of the PaLoc were amplified for all toxigenic strains. Only sequences at the PaLoc integration sites (cdu-2, 162 bp; and cdd-3, 622 bp) were amplified from the non-toxin-producing isolate. Variations may exist in strains that produce both TcdA and TcdB and the toxinotyping scheme describes all strains that exhibit changes within the encoding genes in comparison to a reference strain, VPI (toxinotype 0). All toxigenic isolates belonged to toxinotype 0, sharing the same PCR-RFLP pattern as that of VPI following digestion of the B1 (3088 bp) and A3 (3031 bp) fragments. No alterations were observed in the negative regulatory gene (tcdc) following sequencing of the region. As expected of members of this toxinotype group, these strains did not carry binary toxin genes. Molecular typing PCR ribotyping of the six clinical isolates generated four distinct ribotype profiles comprising seven to 11 DNA fragments of ~ bp, namely, PCR ribotype 050 (APC19 and APC18) and PCR ribotype 005 (APC17 and APC16), and one isolate each of PCR ribotypes 060 and 062 (APC21 and APC14, respectively) (Fig. 2). These isolates were further subtyped to the strain level by PFGE. However, PFGE analysis revealed that both isolates within each toxigenic PCR ribotype group were identical strains, i.e. sharing 100 % similarity of the Dice coefficient (Table 2). DISCUSSION In this study, we set out to examine whether there was an increased incidence of C. difficile carriage in outpatients suffering from IBS and, moreover, whether IBS was an 19.6 kb PaLoc kb 5 3 cda2 cda1 tcdr tcdb tcdk tcda tcdc cdd1 cdd2 cdd3 cdd4 CdtLoc 5211 bp 5 3 cdtr cdta cdtb Fig. 1. C. difficile PaLoc mapped from strain VPI (GenBank accession no. X ) and the putative CdtLoc mapped from isolate CD196 (GenBank accession no. NC_ , nt ). Maps were created using the Clone Manager program version 7 (Science and Educational Software) Journal of Medical Microbiology 61
4 Clostridium difficile carriage in IBS patients Ribotype APC No Fig. 2. PCR ribotype profiles of C. difficile isolates from healthy adults and IBS outpatients identified with Anaerobe Reference Laboratory designations and APC isolate identification numbers. C. difficile isolates from IBS patients belonged to three distinct PCR ribotype groups; APC16 and APC17 belonged to the toxigenic ribotype 005, APC18 and APC19 belonged to toxigenic ribotype 005 and APC21 belonged to the non-toxigenic ribotype 060. The isolate from the control group (APC14) belonged to toxigenic ribotype 062. Size markers are shown in the first and last lanes. additional risk factor for C. difficile acquisition. To achieve this, we screened a group of IBS patients whose diagnosis satisfied the Rome II criteria and for whom established risk factors for C. difficile acquisition were ruled out. Of the 87 IBS outpatients tested, five (5.7 %) carried culturable C. difficile. Among the control group, one subject (1.1 %) carried toxigenic C. difficile (P50.21, Fisher s exact test). Despite this fivefold numerical difference in carriage rate between IBS and control subjects, this difference did not achieve statistical significance, probably due to the relatively small size of the populations studied, but this may also reflect the intrinsic heterogeneity of the IBS population. Thus, current symptom-based diagnostic criteria for IBS, such as the Rome II criteria, select for a heterogeneous group of patients whose symptoms may vary considerably in nature, frequency and severity. Indeed, prior studies have related variations in the faecal microbiota in IBS to differences in symptomatology (Kassinen et al., 2007; Malinen et al., 2005). Our findings indicated that a subpopulation of Table 2. Summary of PCR ribotypes, PFGE pulsotypes and toxigenic status of strains from the IBS and control groups Group Strain PCR ribotype PFGE pulsotype Toxin production IBS APC IBS APC IBS APC IBS APC IBS APC Control APC IBS is predisposed to infection with C. difficile. It is also important to note that there was no relationship between IBS subtype and C. difficile carriage, with only one of the five affected patients having diarrhoea-predominant IBS. What is of particular concern is that four of the strains from the IBS subjects were found to be toxigenic (APC16 19). These strains, together with the toxigenic strain from the control subject, were characterized further in terms of their ability to produce toxins by enzyme immunoassay and by analysis of their PaLoc. In this respect, all toxinproducing isolates belonged to the major toxinotype group 0, sharing the same PCR-RFLP pattern as that of the hightoxin-producing reference strain VPI Notably, toxinotype 0 is clinically significant and is currently the most prevalent group isolated from symptomatic patients suffering from C. difficile infection (Geric et al., 2004; Rupnik, 2008). PCR ribotype profile analysis of these five isolates identified four distinct PCR ribotype groups. PCR ribotype group 005 has been associated previously with C. difficile infection and has been included in the top ten most common ribotypes in England and Northern Ireland (John & Brazier, 2005; Wilcox, 2010), whereas 050, 060 and 062 are all rarer groups. Furthermore, the most common epidemic nosocomial ribotypes, 001 and 106 and the hypervirulent 027, isolated previously from inpatients in some Irish and UK hospitals, were not recovered (Barbut et al., 2007; Drudy et al., 2006). Whilst PFGE is a highly discriminatory fingerprinting technique, it did not discriminate the ribotypes further. Both isolates in each PCR ribotype group were 100 % identical to each other, revealing the prevalence of two distinct strains in these four IBS patients. These strains are probably reflective of the types circulating in this community setting, and similar analyses and larger numbers of strains are necessary to determine whether they have a particular relevance in IBS. The impact of these strains on the pathogenesis of IBS is unknown, but they could exacerbate existing IBS symptoms due to their toxigenic nature. Additionally, further exposure to risk factors for C. difficile infection and antibiotic therapy, in particular, could precipitate overt and even severe pseudomembranous colitis. At the very least, our findings indicate that IBS patients are not immune from C. difficile carriage, a finding that should be borne in mind prior to recommending broad-spectrum antibiotic use in IBS. Clearly, larger studies in this population are merited. ACKNOWLEDGEMENTS This work was funded by the Science Foundation of Ireland Centre for Science, Engineering and Technology (SFI-CSET): the Alimentary Pharmabiotic Centre. We wish to express our sincere gratitude to the following individuals: Dr Jon Brazier (Anaerobe Reference Laboratory, Cardiff) for ribotype profile analysis, Professor Maja Rupnik (University of Maribor, Slovenia) for kindly supplying reference DNA and for her expert advice on toxinotyping, Dr Michael Cronin (Department of Mathematical Sciences, University College Cork, Ireland) for his advice on statistical analyses, and Carmel Wycherley
5 E. M. Clayton and others and Grainne Grealy for their administrative and nursing assistance with clinical specimens and patient data. REFERENCES Barbut, F., Mastrantonio, P., Delmée, M., Brazier, J., Kuijper, E., Poxton, I. & European Study Group on Clostridium difficile (ESGCD) (2007). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13, Borody, T. J., George, L., Andrews, P., Brandl, S., Noonan, S., Cole, P., Hyland, L., Morgan, A., Maysey, J. & Moore-Jones, D. (1989). Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 150, 604. Braun, V., Hundsberger, T., Leukel, P., Sauerborn, M. & von Eichel- Streiber, C. (1996). Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181, Carter, G. P., Lyras, D., Allen, D. L., Mackin, K. E., Howarth, P. M., O Connor, J. R. & Rood, J. I. (2007). Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol 189, Cartwright, C. P., Stock, F., Beekmann, S. E., Williams, E. C. & Gill, V. J. (1995). PCR amplification of rrna intergenic spacer regions as a method for epidemiologic typing of Clostridium difficile. J Clin Microbiol 33, Clayton, E. M., Rea, M. C., Shanahan, F., Quigley, E. M., Kiely, B., Hill, C. & Ross, R. P. (2009). The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104, Curry, S. R., Marsh, J. W., Muto, C. A., O Leary, M. M., Pasculle, A. W. & Harrison, L. H. (2007). tcdc genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45, Drossman, D. A., Camilleri, M., Mayer, E. A. & Whitehead, W. E. (2002). AGA technical review on irritable bowel syndrome. Gastroenterology 123, Drudy, D., Quinn, T., O Mahony, R., Kyne, L., O Gaora, P. & Fanning, S. (2006). High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrb in toxin-a-negative, toxin- B-positive Clostridium difficile. J Antimicrob Chemother 58, Geric, B., Rupnik, M., Gerding, D. N., Grabnar, M. & Johnson, S. (2004). Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53, Jamal, W. Y., Mokaddas, E. M., Verghese, T. L. & Rotimi, V. O. (2002). In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 20, John, R. & Brazier, J. S. (2005). Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 61, Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J. & Palva, A. (2007). The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133, Lyerly, D. M., Saum, K. E., MacDonald, D. K. & Wilkins, T. D. (1985). Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47, Malinen, E., Rinttilä, T., Kajander, K., Mättö, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R. & Palva, A. (2005). Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100, Mättö, J., Maunuksela, L., Kajander, K., Palva, A., Korpela, R., Kassinen, A. & Saarela, M. (2005). Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43, Parkes, G. C., Brostoff, J., Whelan, K. & Sanderson, J. D. (2008). Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103, Pimentel, M., Chow, E. J. & Lin, H. C. (2000). Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95, Pimentel, M., Park, S., Mirocha, J., Kane, S. V. & Kong, Y. (2006). The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145, Popoff, M. R., Rubin, E. J., Gill, D. M. & Boquet, P. (1988). Actinspecific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 56, Quigley, E. M. (2006). Changing face of irritable bowel syndrome. World J Gastroenterol 12, 1 5. Quigley, E. M. (2007). Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 8, 2 7. Rupnik, M. (2008). Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 32, Rupnik, M., Avesani, V., Janc, M., von Eichel-Streiber, C. & Delmée, M. (1998). A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36, Sharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S. & Elhajj, I. (2006). A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101, Simpson, P. J., Stanton, C., Fitzgerald, G. F. & Ross, R. P. (2003). Genomic diversity and relatedness of bifidobacteria isolated from a porcine cecum. J Bacteriol 185, Spigaglia, P. & Mastrantonio, P. (2002). Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40, Spiller, R. C. (2003). Estimating the importance of infection in IBS. Am J Gastroenterol 98, Spiller, R. C. (2007). Role of infection in irritable bowel syndrome. J Gastroenterol 42 (Suppl. 17), Stubbs, S. L., Brazier, J. S., O Neill, G. L. & Duerden, B. I. (1999). PCR targeted to the 16S 23S rrna gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37, Stubbs, S., Rupnik, M., Gibert, M., Brazier, J., Duerden, B. & Popoff, M. (2000). Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186, Wilcox, M. (2010).Clostridium difficile ribotyping network (CDRN) for England and Northern Ireland (2009/2010) Journal of Medical Microbiology 61
Jen KOK*, Qinning WANG, Lee C THOMAS, Gwendolyn L GILBERT. Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of
JCM Accepts, published online ahead of print on 17 August 2011 J. Clin. Microbiol. doi:10.1128/jcm.00752-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationClostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)
Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and
More informationToxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe Michel Warny, Jacques Pepin, Aiqi Fang, George Killgore, Angela Thompson,
More informationIncidence, case fatality and genotypes causing Clostridium difficile infections, Finland, 2008*
ORIGINAL ARTICLE EPIDEMIOLOGY Incidence, case fatality and genotypes causing Clostridium difficile infections, Finland, 2008* S. M. Kotila 1, A. Virolainen 1, M. Snellman 1, S. Ibrahem 1, J. Jalava 2 and
More informationCOMPARISON OF THE PREVALENCE AND GENOTYPIC CHARACTERISTICS OF CLOSTRIDIUM DIFFICILE IN A CLOSED AND INTEGRATED HUMAN AND SWINE POPULATION IN TEXAS
COMPARISON OF THE PREVALENCE AND GENOTYPIC CHARACTERISTICS OF CLOSTRIDIUM DIFFICILE IN A CLOSED AND INTEGRATED HUMAN AND SWINE POPULATION IN TEXAS A Dissertation by KERI NOELLE NORMAN Submitted to the
More informationAn Epidemic, Toxin Gene Variant Strain of Clostridium difficile. abstract
The new england journal of medicine established in 1812 december 8, 25 vol. 353 no. 23 An Epidemic, Toxin Gene Variant Strain of Clostridium difficile L. Clifford McDonald, M.D., George E. Killgore, Dr.P.H.,
More informationREVIEW. Ó 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
REVIEW Emergence of Clostridium difficile-associated disease in North America and Europe E. J. Kuijper 1, B. Coignard 2 and P. Tüll 3 on behalf of the ESCMID Study Group for Clostridium difficile (ESGCD)*,
More informationEmergence of Clostridium difficile-associated disease in Canada, the United States of America and Europe.
Second concept, March 3th, 2006. Emergence of Clostridium difficile-associated disease in Canada, the United States of America and Europe. Background document prepared by dr. Ed. J. Kuijper and dr. Peet
More informationon November 8, 2018 by guest
JCM Accepts, published online ahead of print on December 00 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationI n c r e a s e d n u m b e r o f C lostridium difficile i n f e c t i o n s
Research articles I n c r e a s e d n u m b e r o f C lostridium difficile i n f e c t i o n s a n d p r e va l e n c e o f C lostridium difficile PCR r i b o t y p e 1 in s o u t h e r n Ge r m a n y
More informationC. difficile infection
C. difficile infection Most common cause of infectious diarrhoea in hospital patients 2 major virulence factors: PaLoc toxin A (an enterotoxin) toxin B (a cytotoxin) 3 rd binary toxin Bartlett JG Clin
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More informationObjectives Clostridium difficile Infections, So Many Tests, Which One to Choose?
Objectives Clostridium difficile Infections, So Many Tests, Which One to Choose? March 9, 0 http://www.slh.wisc.edu/outreach-data/event-detail.php?id=03 Raymond P. Podzorski, Ph.D., D(ABMM) Clinical Microbiologist
More informationORIGINAL INVESTIGATION. A Hospital Outbreak of Diarrhea Due to an Emerging Epidemic Strain of Clostridium difficile
ORIGINAL INVESTIGATION A Hospital Outbreak of Diarrhea Due to an Emerging Epidemic Strain of Clostridium difficile Sophia V. Kazakova, MD, MPH, PhD; Kim Ware, RN, BSN, CIC; Brittany Baughman, MS, DVM;
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationClostridium difficile: a problem of concern in developed countries and still a mystery in Latin America
Journal of Medical Microbiology (2012), 61, 169 179 DOI 10.1099/jmm.0.037077-0 Review Correspondence I. T. Balassiano ilana@ioc.fiocruz.br Clostridium difficile: a problem of concern in developed countries
More information(PFGE) Clostridium di$cile
2009 205 (PFGE) Clostridium di$cile 1) 3) 2) 2) 2) 2, 4) 5) 1) 2) 3) 4) 5) 21 5 22 21 8 31 2004 1 2008 12 5 Clostridium di$cile (C. di$cile) 340 248 A /B 141 (56.9) A /B 26 (10.5) A /B 81 (32.7) 136 (PFGE)
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244 Mary N De Almeida,
More informationRapid and Sensitive Loop-Mediated Isothermal Amplification (LAMP) Test for. Gold Standard
JCM Accepts, published online ahead of print on 24 November 2010 J. Clin. Microbiol. doi:10.1128/jcm.01824-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationClostridium difficile Strain NAP-1 Is Not Associated With Severe Disease in a Nonepidemic Setting
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:868 873 Clostridium difficile Strain NAP-1 Is Not Associated With Severe Disease in a Nonepidemic Setting JEFFREY CLOUD,* LAURA NODDIN, AMANDA PRESSMAN,
More informationFecal microbiota transplantation: The When,the How and the Don t. By Dr Rola Hussein
Fecal microbiota transplantation: The When,the How and the Don t By Dr Rola Hussein Introduction Fecal microbiota transplantation (FMT) involves administration of fecal material containing distal gut microbiota
More informationMolecular epidemiology of Clostridium difficile infection in British Columbia, Canada
Molecular epidemiology of Clostridium difficile infection in British Columbia, Canada Agatha Jassem, PhD Senior Scientist, BCCDC Public Health Laboratory Objectives Molecular typing methods for C. difficile
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationThe place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
Research paper The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis Ali Rezaie 1, Shekoufeh Nikfar 2, Mohammad Abdollahi 3 1 Faculty of Medicine, University
More informationESCMID Online Lecture Library. by author
ECDIS-NET: Update on Clostridium difficile epidemiology in Europe 1 E d J. K u i j p e r, S o f i e v a n D o r p a n d D a a n N o t e r m a n s. D e p a r t m e n t o f M e d i c a l M i c r o b i o
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationHost and Pathogen Factors for Clostridium difficile Infection and Colonization
original article Host and Pathogen Factors for Clostridium difficile Infection and Colonization Vivian G. Loo, M.D., Anne-Marie Bourgault, M.D., Louise Poirier, M.D., François Lamothe, M.D., Sophie Michaud,
More informationGut microbiota and health in elderly subjects a role for probiotics? Paul W. O Toole
Gut microbiota and health in elderly subjects a role for probiotics? Paul W. O Toole School of Microbiology, Univ. College Cork, Ireland Alimentary Pharmabiotic Centre, Univ. College Cork, Ireland http://apc.ucc.ie
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationAbdominal Bloating and Distension: What Is the Role of the Microbiota
Dig Dis Sci (2012) 57:4 8 DOI 10.1007/s10620-011-1834-4 REVIEW Abdominal Bloating and Distension: What Is the Role of the Microbiota B. Issa N. A. Wafaei P. J. Whorwell Received: 12 April 2011 / Accepted:
More informationSession VIII: Clostridium difficile: Epidemiology
Session VIII: Clostridium difficile: Epidemiology Controversies in Clostridium difficile Infection Epidemiology McDonald, L.C.* Trends of Clostridium difficile Infection in VA Hospitals and Proposed System
More informationWhole genome sequencing & new strain typing methods in IPC. Lyn Gilbert ACIPC conference Hobart, November 2015
Whole genome sequencing & new strain typing methods in IPC Lyn Gilbert ACIPC conference Hobart, November 2015 Why do strain typing? Evolution, population genetics, geographic distribution 2 Why strain
More informationESCMID Online Lecture Library. by author
Factors influencing the results of metronidazole resistance testing Elisabeth Nagy Institute of Clinical Microbiology, University of Szeged, National Anaerobe Reference Laboratory, Szeged, Hungary Postgraduate
More informationDETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:
More information... SELECTED ABSTRACTS...
... SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on irritable bowel syndrome, were selected for their relevance to this supplement. A Technical Review for
More informationNew genomic typing method MLST
New genomic typing method MLST Bon KIMURA fingerprinting PFGE DNA multilocus sequence typingmlst alleles PFGE MLST 1990 PCR 1 PCR DNA PFGE 1 PFGE RAPDrandomly amplified polymorphic DNA 3 AFLPAmplified
More informationSherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine
Sherwood L. Gorbach, MD Professor of Public Health, Medicine, and Microbiology Tufts University School of Medicine Chief Scientific Officer, Optimer Pharmaceuticals, Inc. Conflicts: Chief Scientific Officer,
More informationReference assays for Clostridium difficile infection: one or two gold standards?
1 Centre for Infection, Division of Cellular and Molecular Medicine, St George s University of London, Cranmer Terrace, London, UK 2 Microbiology, Leeds Teaching Hospitals and University of Leeds, Old
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationDoes Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
ISPUB.COM The Internet Journal of Infectious Diseases Volume 15 Number 1 Does Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
More informationStool bench. Cultures: SARAH
Stool bench The bacteria found in stool are representative of the bacteria that are present in the digestive system (gastrointestinal tract). Certain bacteria and fungi called normal flora inhabit everyone's
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationIrritable bowel syndrome (IBS) is a functional gastrointestinal. Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome INTRODUCTION
Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome by Mark Pimentel Although several pathophysiologic models have been suggested, the etiology of irritable bowel syndrome (IBS) is unknown.
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationClostridium difficile: An Overview
Clostridium difficile: An Overview CDI Webinar July 11, 2017 PUBLIC HEALTH DIVISION Acute and Communicable Disease Prevention Section Outline Background Microbiology Burden Pathogenesis Diagnostic testing
More informationLaboratory diagnosis of Clostridium difficile infection
Review Article Page 1 of 5 Laboratory diagnosis of Clostridium difficile infection Katherine Kendrick Mercer University School of Medicine (SOM), Navicent Health, Macon, GA, USA Correspondence to: Katherine
More informationPrevalence and diversity of Clostridium difficile strains in infants
Journal of Medical Microbiology (2011), 60, 1112 1118 DOI 10.1099/jmm.0.029736-0 Prevalence and diversity of Clostridium difficile strains in infants Clotilde Rousseau, 1,2 Ludovic Lemée, 3,4 Alban Le
More informationcomplicating inflammatory bowel disease
Gut, 1982, 23, 410-414 Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease M R B KEIGHLEY*, DENISE YOUNGS, MARGARET JOHNSON, R N ALLAN, and D W BURDON From The General
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.15 Rapid Diagnosis of Toxigenic Clostridium
More informationSMT19969: A Selective Therapy for C. difficile Infection
SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationClostridium difficile 027, A Southern Hemisphere Perspective Dr. David Hammer, Medlab South, New Zealand A Webber Training Teleclass
Clostridium difficile 027 A Southern Hemisphere Perspective THE PRESS 6 July 2006 Dr. David Hammer Microbiology Registrar Medlab South Canterbury, NZ Total Annual Cost of Nosocomial Infection USA US$ 7
More informationUnderstanding Gallibacterium-Associated Peritonitis in the Commercial Egg-Laying Industry
Understanding Gallibacterium-Associated Peritonitis in the Commercial Egg-Laying Industry Timothy J. Johnson A, Lisa K. Nolan B, and Darrell W. Trampel C A University of Minnesota, Department of Veterinary
More informationC lostridium difficile is an anaerobic Gram positive bacillus
673 GASTROINTESTINAL INFECTION Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of S S Johal, J Hammond, K Solomon, P D James, Y R Mahida...
More informationThis is a repository copy of Clostridium difficile infection: advances in epidemiology, diagnosis and transmission.
This is a repository copy of Clostridium difficile infection: advances in epidemiology, diagnosis and transmission. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/93246/
More informationMolecular epidemiology and drug resistance mechanism of Salmonella species especially in S. Typhi strains isolated in Bangladesh
Molecular epidemiology and drug resistance mechanism of Salmonella species especially in S. Typhi strains isolated in Bangladesh Dr. Kaisar Ali Talukder Senior Scientist Icddr,b This presentation will
More informationClostridium difficile Associated Diarrhea: A Review and Update on Changes in Disease Virulence and Treatment Response
Clostridium difficile Associated Diarrhea: A Review and Update on Changes in Disease Virulence and Treatment Response April D. Miller, PharmD, Kelly M. Smith, PharmD, P. Shane Winstead, PharmD, and Craig
More informationSESSION VII CLOSTRIDIUM DIFFICILE: EPIDEMIOLOGY
SESSION VII Healthcare and Community-Associated Clostridium difficile Infection in North America McDonald, L.C.* Emerging Clostridium difficile Strains in North America 3 Limbago, B.M.* Molecular Epidemiology
More informationClostridium difficile associated diarrhoea HIV and CD4 count in Malawi
Clostridium difficile associated diarrhoea HIV and CD4 count in Malawi For Transactions: Short Communications - 800 words, 1 table or figure, abstract 100 words, 5 references. Michael BJ Beadsworth, Lauren
More informationToxigenic Clostridium difficile is recognized as. Predominance of Clostridium difficile 027 during a five-year period in Bolzano, Northern Italy
Le Infezioni in Medicina, n. 1, 13-20, 2017 ORIGINAL ARTICLE 13 Predominance of Clostridium difficile 027 during a five-year period in Bolzano, Northern Italy Richard Aschbacher 1, Alexander Indra 2, Christian
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationRecurrent Clostridium difficile Disease: Association of Relapse with BI/NAP1/027. Scott R. Curry 1, Lee H. Harrison 1
JCM Accepts, published online ahead of print on 10 October 2012 J. Clin. Microbiol. doi:10.1128/jcm.02291-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Recurrent Clostridium
More informationTreatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department
Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Therapy for Patients with Irritable Bowel Syndrome without Constipation Mark Pimentel, M.D., Anthony Lembo, M.D., William D. Chey,
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationClostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126
RESEARCH ARTICLE Kachrimanidou et al., Journal of Medical Microbiology 2017;66:1774 1781 DOI 10.1099/jmm.0.000623 Clostridium difficile infections in a university hospital in Greece are mainly associated
More informationClostridium difficile infection (CDI)- what s new in diagnosis and treatment; target of antibiotic stewardship
Clostridium difficile infection (CDI)- what s new in diagnosis and treatment; target of antibiotic stewardship Thomas J. Louie, MD, FRCPC Medical Director, IP&C, Calgary Health Region; Professor of Medicine,
More informationS (15) DOI: doi: /j.diagmicrobio Reference: DMB 13832
Accepted Manuscript A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype-027 strain with reduced susceptibility to vancomycin and metronidazole
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More informationDiphtheria infections caused by the different toxigenic biotypes of Corynebacterium diphtheriae
JCM Accepts, published online ahead of print on 5 December 00 J. Clin. Microbiol. doi:0.8/jcm.054-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More informationThe Challenges Posed by Reemerging Clostridium difficile Infection
EMERGING INFECTIONS James M. Hughes and Mary E. Wilson, Section Editors INVITED ARTICLE The Challenges Posed by Reemerging Clostridium difficile Infection David B. Blossom and L. Clifford McDonald Division
More informationA first molecular characterization of Listeria monocytogenes isolates circulating in humans from 2009 to 2014 in the Italian Veneto region
Short communication A first molecular characterization of Listeria monocytogenes isolates circulating in humans from 2009 to 2014 in the Italian Veneto region Cristiano Salata 1,2, Paola Lisotto 1, Caterina
More informationClinical Application of Polymerase Chain Reaction to Diagnose Clostridium difficile in Hospitalized Patients With Diarrhea
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:669 674 Clinical Application of Polymerase Chain Reaction to Diagnose Clostridium difficile in Hospitalized Patients With Diarrhea MICHAEL S. MORELLI, SUSAN
More informationThe epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community. J Scott Weese DVM DVSc DipACVIM
The epidemiology of Clostridium difficile infection (CDI) in hospitals, longterm care and the community J Scott Weese DVM DVSc DipACVIM C. difficile Gram positive anaerobic sporeforming bacterium first
More informationNicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata
Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society
More informationOvercoming barriers to effective recognition and diagnosis of Clostridium difficile infection
REVIEW 10.1111/1469-0691.12057 Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection M. H. Wilcox Department of Microbiology, Old Medical School, Leeds Teaching
More information! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery
Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal
More informationYonsei University College of Medicine, Seoul, South Korea
Journal of Medical Microbiology (2014), 63, 1542 1551 DOI 10.1099/jmm.0.070672-0 Epidemiology and clinical features of toxigenic culture-confirmed hospital-onset Clostridium difficile infection: a multicentre
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationXifaxan. Xifaxan (rifaximin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.34 Subject: Xifaxan Page: 1 of 6 Last Review Date: December 8, 2017 Xifaxan Description Xifaxan (rifaximin)
More informationMaterials EXCLUSION CRITERIA INCLUSION CRITERIA
Bifidobacteria numbers in colon of children with inflammatory bowel disease (IBD). Gosiewski T 1, Kochan P 1,StrusM 1, Brzychczy-Wloch M 1, Drzewiecki A 1, Kowalska-Duplaga K 2, Wedrychowicz A 2, Jedynak-Wasowicz
More informationPersistence of Skin Contamination and Environmental Shedding of Clostridium difficile during and after Treatment of C. difficile Infection
infection control and hospital epidemiology january 2010, vol. 31, no. 1 original article Persistence of Skin Contamination and Environmental Shedding of Clostridium difficile during and after Treatment
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationINFECTION WITH TOXIN A-NEGATIVE, TOXIN B-NEGATIVE, BINARY TOXIN- POSITIVE CLOSTRIDIUM DIFFICILE IN A YOUNG PATIENT WITH ULCERATIVE COLITIS
JCM Accepted Manuscript Posted Online 9 September 2015 J. Clin. Microbiol. doi:10.1128/jcm.01810-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13
More informationMolecular typing insight on diversity and antimicrobial resistance of Campylobacter jejuni from Belgian chicken meat
Molecular typing insight on diversity and antimicrobial resistance of Campylobacter jejuni from Belgian chicken meat Ihab Habib Ghent University Department of Public Health and Food Safety. Contents: Molecular
More informationICU-Onset Clostridium difficile Infection in a University Hospital in China: A Prospective Cohort Study
ICU-Onset Clostridium difficile Infection in a University Hospital in China: A Prospective Cohort Study Xiaohui Wang 1,2, Lin Cai 3, Rujia Yu 1,2, Wenzhi Huang 4, Zhiyong Zong 1,2,4 * 1 Center of Infectious
More informationClostridium difficile infection in an endemic setting in the Netherlands
Eur J Clin Microbiol Infect Dis (2011) 30:587 593 DOI 10.1007/s10096-010-1127-4 ARTICLE Clostridium difficile infection in an endemic setting in the Netherlands M. P. M. Hensgens & A. Goorhuis & C. M.
More information